Replies to post #233857 on Biotech Values

[miljenko]

ABUS 5.07 - here's the BNTX agreement with Genevant from 7/4/18

That deal was primarily for liver-targeting approach and oncology. However, it can easily be expanded to general infectious disease, where vaccines construct will come under LNP IP protection.

MRNA will need LNP IP licensure, IMO.